Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.
作者信息
Verweij J, Krzemieniecki K, Kok T, Poveda A, van Pottelsberghe C, van Glabbeke M, Mouridsen H
机构信息
Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.
出版信息
Eur J Cancer. 1993;29A(2):208-9. doi: 10.1016/0959-8049(93)90177-h.
PMID:8422284
Abstract
The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas. No responses were seen in 18 evaluable patients. Toxicity consisted mainly of nausea/vomiting. It is concluded that oral miltefosine has no activity in soft tissue sarcoma.
摘要
Zotero 插件